Fourth, mutant TP53 is generally considered to be “undruggable.” In recent years, although some studies have reported the development of a variety of small-molecule compounds or peptide drugs targeting mutant TP53, few drugs have entered clinical trials, and no drugs targeting mutant TP53 have been approved for tumor treatment. This evidence concerns the gene TP53 and neoplasm.